

2017 IWMF Educational Forum – Poster Presentations

The following posters were presented originally at the 9th International Workshop on Waldenstrom’s Macroglobulinemia in October 2016 in Amsterdam. They represent the work of young researchers, all of whom received Young Investigator Awards (YIAs) at the Workshop and most of whom were sponsored by the IWMF or its International Affiliates. Nearly all the Young Investigators gave us permission to reproduce their posters for the 2017 IWMF Educational Forum in Phoenix, AZ, and to place them on our website.

Click on the title of each poster below to see a PDF file of it. Each one includes a short lay summary of the poster written by the IWMF. In most cases, you may wish to zoom in to enlarge the text of the poster to make it more readable.

Poster Title (click title to see poster and lay summary)	Young Investigator
MYD88 and CXCR4 analyses in lymphoplasmacytic lymphoma routine diagnostics need to consider mutations outside the L265P hotspot and follow-up testing	Constance Baer – MLL Munich Leukemia Laboratory, Munich, Germany
Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells that is Accompanied by ERK1/2 Hyperactivation, and is Targeted by the Addition of the ERK1/2 Inhibitor Ulixertinib	George Chen – Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA
RETROSPECTIVE ANALYSIS OF 77 CASES OF TRANSFORMED WALDENSTROM MACROGLOBULINEMIA. A STUDY ON BEHALF OF THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO)	Eric Durot – Department of Hematology, Centre Hospitalier Universitaire de Reims, France
Chromosome 6q deletions are common in Waldenström’s Macroglobulinemia, and target regulatory genes for MYD88, CXCR4 and BCL2 signaling	Maria Luisa Guerrara – Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
The high risk of symptomatic hyperviscosity in patients with high serum IgM levels can be used to support initiation of treatment in Waldenström macroglobulinemia	Joshua N. Gustine – Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA
Identifying a role for PD-1/PD-L1/PD-L2 signaling in Waldenstrom’s Macroglobulinemia	Shahrazad Jalali – Division of Hematology, Mayo Clinic, Rochester, MN, USA
CHARACTERIZATION OF ENDOGENOUS CXCR4 INHIBITORY PEPTIDES TO TARGET WALDENSTRÖM’S MACROGLOBULINEMIA	Lisa Kaiser – Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
Creation of Waldenstrom Macroglobulinemia Digital Avatars Using Machine-Learning and Systems Biology Algorithms Exposes Novel and Clinically Relevant Therapeutic Opportunities	Aneel Paulus – Mayo Clinic, Jacksonville, FL, USA
Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom’s Macroglobulinemia and associates with CXCR4 mutation status	Nickolas Tsakmaklis – Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA
Prevalence of MYD88 L265P mutation in IgM anti-MAG peripheral neuropathy	Josephine M. Vos – Antonius Ziekenhuis Nieuwegein (AZN), Nieuwegein and UMC Utrecht, The Netherlands